Escandallo, Lyka L.
HRN: 16-46-97 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/30/2023
CEFUROXIME 750MG (VIAL)
06/30/2023
07/06/2023
IV
320mg
Q8
Urti
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes